Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Operating Leases (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Operating Leases for 5 consecutive years, with $19.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Operating Leases fell 7.19% to $19.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $19.7 million, a 7.19% decrease, with the full-year FY2025 number at $19.7 million, down 7.19% from a year prior.
  • Operating Leases was $19.7 million for Q4 2025 at Janux Therapeutics, down from $20.4 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $24.5 million in Q4 2022 to a low of $23000.0 in Q3 2021.
  • A 5-year average of $21.0 million and a median of $22.4 million in 2024 define the central range for Operating Leases.
  • Peak YoY movement for Operating Leases: soared 104647.83% in 2022, then decreased 8.44% in 2025.
  • Janux Therapeutics' Operating Leases stood at $23000.0 in 2021, then skyrocketed by 106604.35% to $24.5 million in 2022, then decreased by 6.18% to $23.0 million in 2023, then decreased by 7.6% to $21.3 million in 2024, then dropped by 7.19% to $19.7 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Operating Leases are $19.7 million (Q4 2025), $20.4 million (Q3 2025), and $20.3 million (Q2 2025).